Use of mTOR inhibitor and chloroquine for treating cancer
US11285143B2 · kind B2 · utility
0Cited by
0References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 8, 2017 |
| Grant date | Mar 29, 2022 |
| Priority date | — |
| Expiry date | Nov 23, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K16/2818
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein are uses of a mammalian target of rapamycin (mTOR) inhibitor and chloroquine or analogue thereof in the manufacture of a medicament for treating cancer patients who are not responsive to a hormone therapy and an immunotherapy. In particular, the medicament is used during the hormone therapy and the immunotherapy to sensitize the patients to the hormone therapy and the immunotherapy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.